NTS 071
Alternative Names: NTS-071Latest Information Update: 20 Dec 2024
Price :
$50 *
At a glance
- Originator NUTSHELL Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 23 Oct 2024 Preclinical trials in Solid tumours in China (PO), prior to October 2024 (Nutshell Therapeutics pipeline, December 2024)
- 23 Oct 2024 Pharmacodynamics, pharmacokinetics and safety data from preclinical trials in Solid tumours presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR Symposium-2024)